TY - JOUR
T1 - Relative dose intensity of taxane-based chemotherapy in breast cancer patients in a tertiary hospital
AU - Helwani, Amira M.
AU - Al Suleimani, Yousuf M.
AU - Al Baimani, Khalid
AU - Abdelrahman, Aly M.
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/11/15
Y1 - 2023/11/15
N2 - INTRODUCTION: Breast cancer (BC) is the most diagnosed tumor among women worldwide. The aim of this study was to investigate the incidence and causes of low relative dose intensity (RDI) < 85% for taxane-based chemotherapy regimens used in the treatment of BC in Sultan Qaboos University Hospital (SQUH).METHODS: This was a retrospective study that included 303 BC patients, treated with taxane-based chemotherapy protocols at SQUH. RDI was calculated for each chemotherapy regimen and causes and predictors of low RDI < 85% were identified. Prophylactic and therapeutic supportive measures for certain toxicities were studied.RESULTS: 50.8% of the patients had neoadjuvant chemotherapy, 38% had adjuvant chemotherapy, and 11.2% of patients were given palliative treatment. AC-T and AC-THP were the most used regimens (40.3% and 17.2%). Mean RDI of used taxane-based chemotherapy regimens was 93.4%. Dose delays, dose reductions, and treatment discontinuation occurred in 36.6%, 14.8%, and 11.5%, respectively. Thirty-eight patients (12.5%) had low RDI < 85% which was reduced to 9.9% after the use of an alternative taxane. Age and chemotherapy intent were significant risk factors. 83.8% received primary granulocyte colony stimulating factor.CONCLUSION: An optimal RDI greater than 85% was achieved in most cases. Furthermore, prophylactic and therapeutic supportive measures were widely used.
AB - INTRODUCTION: Breast cancer (BC) is the most diagnosed tumor among women worldwide. The aim of this study was to investigate the incidence and causes of low relative dose intensity (RDI) < 85% for taxane-based chemotherapy regimens used in the treatment of BC in Sultan Qaboos University Hospital (SQUH).METHODS: This was a retrospective study that included 303 BC patients, treated with taxane-based chemotherapy protocols at SQUH. RDI was calculated for each chemotherapy regimen and causes and predictors of low RDI < 85% were identified. Prophylactic and therapeutic supportive measures for certain toxicities were studied.RESULTS: 50.8% of the patients had neoadjuvant chemotherapy, 38% had adjuvant chemotherapy, and 11.2% of patients were given palliative treatment. AC-T and AC-THP were the most used regimens (40.3% and 17.2%). Mean RDI of used taxane-based chemotherapy regimens was 93.4%. Dose delays, dose reductions, and treatment discontinuation occurred in 36.6%, 14.8%, and 11.5%, respectively. Thirty-eight patients (12.5%) had low RDI < 85% which was reduced to 9.9% after the use of an alternative taxane. Age and chemotherapy intent were significant risk factors. 83.8% received primary granulocyte colony stimulating factor.CONCLUSION: An optimal RDI greater than 85% was achieved in most cases. Furthermore, prophylactic and therapeutic supportive measures were widely used.
KW - Taxanes
KW - breast cancer
KW - chemotherapy
KW - relative dose intensity
KW - toxicities
UR - http://www.scopus.com/inward/record.url?scp=85176964899&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176964899&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/e70ea881-4d88-3fa6-bbed-6ed2434b4192/
U2 - 10.1177/10781552231214467
DO - 10.1177/10781552231214467
M3 - Article
C2 - 37968875
AN - SCOPUS:85176964899
SN - 1078-1552
SP - 10781552231214467
JO - Journal of Oncology Pharmacy Practice
JF - Journal of Oncology Pharmacy Practice
ER -